Potential of mesenchymal stem cells for the therapy of autoimmune diseases

Expert Review of Clinical Immunology

Volumn 6, Issue 2, 2010, Pages 211-218

  Pistoia, Vito ^a   Raffaghello, Lizzia ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

Autoimmune disorder; Immunosuppression; Mesenchymal; Stem cell; Stromal

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DIABETES MELLITUS; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SAFETY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THERAPY EFFECT;

ANIMALS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GUIDED TISSUE REGENERATION; HUMANS; IMMUNOSUPPRESSION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS;

EID: 77949433853     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.86     Document Type: Review

References (70)

1. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411), 143-147 (1999).
2. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8(9), 726-736 (2008).
3. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell. Sci. 119(Pt 11), 2204-2213 (2006).
4. Katz AJ, Tholpady A, Tholpady SS et al. Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells. Stem Cells 23(3), 412-423 (2005).
5. Horwitz EM, Le Blanc K, Dominici M et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7(5), 393-395 (2005).
6. Friedenstein AJ, Chailakhyan RK, Latsinik NV et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17(4), 331-340 (1974).
7. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 110(10), 3499-3506 (2007).
8. Muguruma Y, Yahata T, Miyatake H et al. Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment. Blood 107 (5), 1878-1887 (2006).
9. Sacchetti B, Funari A, Michienzi S et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131(2), 324-336 (2007).
10. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 5(3), 309-313 (1999).
11. Wakitani S, Nawata M, Tensho K et al. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. J. Tissue Eng. Regen. Med. 1(1), 74-79 (2007).
12. Petersen BE, Bowen WC, Patrene KD et al. Bone marrow as a potential source of hepatic oval cells. Science 284(5417), 1168-1170 (1999).
13. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 98(5), 1076-1084 (2006).
14. Tyndall A, Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplant. 43(11), 821-828 (2009).
15. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10), 3838-3843 (2002).
16. Selmani Z, Naji A, Zidi I et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26(1), 212-222 (2008).
17. Spaggiari GM, Capobianco A, Abdelrazik H et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111(3), 1327-1333 (2008).
18. Krampera M, Cosmi L, Angeli R et al. Role for interferon-g in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24(2), 386-398 (2006).
19. Morandi F, Raffaghello L, Bianchi G et al. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells 26(5), 1275-1287 (2008).
20. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4), 1815-1822 (2005).
21. Glennie S, Soeiro I, Dyson PJ et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105(7), 2821-2827 (2005).
22. Nauta AJ, Kruisselbrink AB, Lurvink E et al. Mesenchymal stem cells inhibit generation and function of both CD34+- derived and monocyte-derived dendritic cells. J. Immunol. 177(4), 2080-2087 (2006).
23. Spaggiari GM, Capobianco A, Becchetti S et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107(4), 1484-1490 (2006).
24. Raffaghello L, Bianchi G, Bertolotto M et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26(1), 151-162 (2008).
25. Prigione I, Benvenuto F, Bocca P et al. Reciprocal interactions between human mesenchymal stem cells and gd T cells or invariant natural killer T cells. Stem Cells 27(3), 693-702 (2009).
26. Rasmusson I, Uhlin M, Le Blanc K et al. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J. Leukoc. Biol. 82(4), 887-893 (2007).
27. Corcione A, Benvenuto F, Ferretti E et al. Human mesenchymal stem cells modulate B-cell functions. Blood 107(1), 367-372 (2006).
28. Traggiai E, Volpi S, Schena F et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 26(2), 562-569 (2008).
29. Stagg J, Pommey S, Eliopoulos N et al. Interferon-g-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 107(6), 2570-2577 (2006).
30. Liotta F, Angeli R, Cosmi L et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26(1), 279-289 (2008).
31. Opitz CA, Litzenburger UM, Lutz C et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3- dioxygenase-1 via interferon-b and protein kinase R. Stem Cells 27(4), 909-919 (2009).
32. Djouad F, Plence P, Bony C et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102(10), 3837-3844 (2003).
33. Ruster B, Gottig S, Ludwig RJ et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 108(12), 3938-3944 (2006).
34. Son BR, Marquez-Curtis LA, Kucia M et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24(5), 1254-1264 (2006).
35. Sordi V, Malosio ML, Marchesi F et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106(2), 419-427 (2005).
36. Devine SM, Cobbs C, Jennings M et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101(8), 2999-3001 (2003).
37. Zappia E, Casazza S, Pedemonte E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106(5), 1755-1761 (2005).
38. Constantin G, Marconi S, Rossi B et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 27(10), 2624-2635. (2009).
39. Rafei M, Birman E, Forner K et al. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol. Ther. 17(10), 1799 - 1803 (2009).
40. Rafei M, Campeau PM, Aguilar-Mahecha A et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 182(10), 5994-6002 (2009).
41. Augello A, Tasso R, Negrini SM et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 56(4), 1175-1186 (2007).
42. Gonzalez MA, Gonzalez-Rey E, Rico L et al. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum. 60(4), 1006-1019 (2009).
43. Djouad F, Fritz V, Apparailly F et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor a in collagen-induced arthritis. Arthritis Rheum. 52(5), 1595-1603 (2005).
44. Sun L, Akiyama K, Zhang H et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27(6), 1421-1432 (2009).
45. Zhou K, Zhang H, Jin O et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell. Mol. Immunol. 5(6), 417-424 (2008).
46. Deng W, Han Q, Liao L et al. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol. 24(7), 458-463 (2005).
47. Garcia-Olmo D, Herreros D, Pascual I et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a Phase II clinical trial. Dis. Colon Rectum 52(1), 79-86 (2009).
48. Gonzalez MA, Gonzalez-Rey E, Rico L et al. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136(3), 978-989 (2009).
49. Urban VS, Kiss J, Kovacs J et al. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 26 (1), 244-253 (2008).
50. Lee RH, Seo MJ, Reger RL et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc. Natl Acad. Sci. USA 103(46), 17438-17443 (2006).
51. Fiorina P, Jurewicz M, Augello A et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune Type 1 diabetes. J. Immunol. 183(2), 993-1004 (2009).
52. Madec AM, Mallone R, Afonso G et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 52(7), 1391-1399 (2009).
53. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30(1), 42-48 (2002).
54. Munoz JR, Stoutenger BR, Robinson AP et al. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc. Natl Acad. Sci. USA 102(50), 18171-18176 (2005).
55. Rivera FJ, Couillard-Despres S, Pedre X et al. Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells. Stem Cells 24(10), 2209-2219 (2006).
56. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419), 1439-1441 (2004).
57. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a Phase II study. Lancet 371(9624), 1579-1586 (2008).
58. Ning H, Yang F, Jiang M et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22(3), 593-599 (2008).
59. Vianello F, Dazzi F. Mesenchymal stem cells for graft-versus-host disease: a double edged sword? Leukemia 22(3), 463-465 (2008).
60. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J. Immunol. 4(1), 50-57 (2007).
61. Vija L, Farge D, Gautier JF et al. Mesenchymal stem cells: stem cell therapy perspectives for Type 1 diabetes. Diabetes Metab. 35(2), 85-93 (2009).
62. Christopeit M, Schendel M, Foll J et al. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 22(5), 1062-1064 (2008).
63. Bocelli-Tyndall C, Bracci L, Spagnoli G et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford) 46(3), 403-408 (2007).
64. Bacigalupo A, Valle M, Podesta M et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp. Hematol. 33(7), 819-827 (2005).
65. Sensebe L, Bourin P. Mesenchymal stem cells for therapeutic purposes. Transplantation 87(9 Suppl.), S49-S53 (2009).
66. Bernardo ME, Zaffaroni N, Novara F et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 67(19), 9142-9149 (2007).
67. Rosland GV, Svendsen A, Torsvik A et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 69(13), 5331-5339 (2009).
68. Tolar J, Nauta AJ, Osborn MJ et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25(2), 371-379 (2007).
69. Haniffa MA, Wang XN, Holtick U et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J. Immunol. 179(3), 1595-1604 (2007).
70. Bocelli-Tyndall C, Barbero A, Candrian C et al. Human articular chondrocytes suppress in vitro proliferation of anti-CD3 activated peripheral blood mononuclear cells. J. Cell. Physiol. 209(3), 732-734 (2006).